Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

5.59
+0.10001.82%
Pre-market: 5.610.0200+0.36%09:05 EDT
Volume:3.04M
Turnover:16.95M
Market Cap:1.14B
PE:-9.67
High:5.64
Open:5.54
Low:5.50
Close:5.49
52wk High:7.01
52wk Low:3.08
Shares:204.66M
Float Shares:198.20M
Volume Ratio:1.85
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5782
EPS(LYR):-0.5344
ROE:-105.48%
ROA:-50.15%
PB:7.96
PE(LYR):-10.46

Loading ...

Savara Grants New Hires Options for 74,500 Shares at $5.37, RSUs for 64,500 Shares

Reuters
·
Aug 21

Savara Merilis Presentasi Korporasi Tentang Penyakit Paru Langka Autoimmune PAP Dan Kandidat Terapi Inhalasi Molbreevi

Reuters
·
Aug 12

Savara Q2 EPS $(0.16) Misses $(0.14) Estimate

Benzinga Earnings
·
Aug 12

Savara Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Savara Q2 Loss Widens as Operating Expenses Rise

Reuters
·
Aug 12

Savara Rugi Bersih Q2 FY26 Melebar 32,3% Ke USD 40,2 Juta

Reuters
·
Aug 12

Savara Q2 Net Income USD -40.228 Million

Reuters
·
Aug 12

Savara - European and Australian Patent Offices Grant Molbreevi Patents Until March 2041

THOMSON REUTERS
·
Aug 12

Savara - Molbreevi MAAS Under Review by Ema and U.k's Mhra; Decisions Expected Q1 2027 and Q4 2026, Respectively

THOMSON REUTERS
·
Aug 12

Savara announces EPO granted a patent covering formulation of Molbreevi

TIPRANKS
·
Jul 30

Savara Says Europe, Australia Grant Molbreevi Liquid Formulation Patents Through 2041

Reuters
·
Jul 30

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of Molbreevi*, Providing Protection in Europe and Australia Until March 2041

THOMSON REUTERS
·
Jul 30

Savara Posts Corporate Presentation Focused on Autoimmune Pulmonary Alveolar Proteinosis and Molbreevi Program

Reuters
·
Jul 16

Palvella Therapeutics Appoints Savara CEO Matt Pauls to Board of Directors

Reuters
·
Jun 30

Does FDA Review of MOLBREEVI and Insider Sales Shift the Bull Case For Savara (SVRA)?

Simply Wall St.
·
Jun 30

Is Savara (SVRA) Expensive As Its Rally Puts A Premium On Book Value?

Simply Wall St.
·
Jun 28

Savara CFO David Lowrance disposes of 580,187 common shares worth $3.31 million

Reuters
·
Jun 23

Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA)

TIPRANKS
·
Jun 15

Savara grants new-hire equity awards for 87,000 shares, options priced at $5.27

Reuters
·
Jun 13

Savara CFO Steps Down Citing Health-Related Reasons

Dow Jones
·
Jun 09